Asia Pacific Cancer Supportive Care Drugs Market Size & Outlook
Asia Pacific cancer supportive care drugs market, 2018-2030 (US$M)
Related Markets
Asia Pacific cancer supportive care drugs market highlights
- The Asia Pacific cancer supportive care drugs market generated a revenue of USD 1,771.5 million in 2023.
- The market is expected to grow at a CAGR of -0.5% from 2024 to 2030.
- In terms of segment, antiemetics was the largest revenue generating therapeutic class in 2023.
- NSAIDs and Others is the most lucrative therapeutic class segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 1,771.5 million |
| Market revenue in 2030 | USD 1,716.4 million |
| Growth rate | -0.5% (CAGR from 2023 to 2030) |
| Largest segment | Antiemetics |
| Fastest growing segment | NSAIDs and Others |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | G-CSFs (Granulocyte-colony Stimulating Factors), ESAs (Erythropoiesis Stimulating Agents), Antiemetics, Bisphosphonates, Opioids, NSAIDs and Others |
| Key market players worldwide | Amgen Inc, Merck & Co Inc, Johnson & Johnson, Heron Therapeutics Inc, Novartis AG ADR, GSK PLC, Roche Holding AG ADR, Helsinn Healthcare |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 13.3% of the global cancer supportive care drugs market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,716.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Supportive Care Drugs Market Scope
Cancer Supportive Care Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific cancer supportive care drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer supportive care drugs market will help companies and investors design strategic landscapes.
Antiemetics was the largest segment with a revenue share of 25.67% in 2023. Horizon Databook has segmented the Asia Pacific cancer supportive care drugs market based on g-csfs (granulocyte-colony stimulating factors), esas (erythropoiesis stimulating agents), antiemetics, bisphosphonates, opioids, nsaids and others covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific is expected to witness market decline over the forecast period. The rapid uptake of biosimilar and generic drugs and restriction on opioid prescriptions coupled with usage of traditional medicine for cancer supportive care are factors for the declining market. Improvements in healthcare infrastructure and increase in the number of government initiatives will drive market growth.
Moreover, economic development in countries, such as India and China, is expected to drive market growth. Large population and low per capita income in Asia Pacific have led to high demand for affordable treatment options. Hospitals receive reimbursement from governments for treatment in some of the more developed economies in Asia Pacific. Underdeveloped economies provide little to no reimbursement for cancer supportive care medicines.
However, these countries are expected to change their guidelines over the forecast period. Improving healthcare reimbursement guidelines, presence of large target population, and high unmet therapeutic needs are expected to provide a lucrative opportunities companies in this region.
Reasons to subscribe to Asia Pacific cancer supportive care drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific cancer supportive care drugs market databook
-
Our clientele includes a mix of cancer supportive care drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific cancer supportive care drugs market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific cancer supportive care drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific cancer supportive care drugs market size, by country, 2018-2030 (US$M)
Asia Pacific Cancer Supportive Care Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
